Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis

American Journal of Gastroenterology

Volumn 98, Issue 7, 2003, Pages 1599-1604

  Jover, Rodrigo ^a   Compañy, Luís ^b   Gutiérrez, Ana ^b   Zapater, Pedro ^b   Pérez Serra, Juan ^b   Girona, Eva ^b   Aparicio, José R ^b   Pérez Mateo, Miguel ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MANGANESE;

ADULT; AGED; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; COGNITIVE DEFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MALE; MINI MENTAL STATE EXAMINATION; MULTIVARIATE ANALYSIS; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0038796001     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07528.x     Document Type: Article

References (45)

1. Gitlin N. Subclinical portal-systemic encephalopathy. Am J Gastroenterol 1988;83:8-11.
2. Blei AT. Hepatic encephalopathy. In: Bircher J, Benhamou JP, McIntyre N, et al., eds. Oxford textbook of clinical hepatology. Oxford: Oxford University Press, 1999:765-83.
3. Quero JC, Schalm SW. Subclinical hepatic encephalopathy. Semin Liver Dis 1996;16:321-8.
4. Kardel T, Lund Y, Olsen PZ, et al. Encephalopathy and portacaval anastomosis. Scand J Gastroenterol 1970;5:681-5.
5. Rikkers L, Jenko P, Rudman D, et al. Subclinical hepatic encephalopathy: Detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978;75:462-9.
6. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45-9.
7. Tarter RE, Hegedus AM, Van Thiel DH, et al. Nonalcoholic cirrhosis associated with neuropsychological dysfunction in absence of overt evidence of hepatic encephalopathy. Gastroenterology 1984;86:1421-7.
8. Romero Gómez M, Boza F, García F, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001;96:2718-23.
9. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986;3:75-82.
10. McCrea M, Córdoba J, Vessey G, et al. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996;53:758-63.
11. Kullmann F, Hollerbach S, Holstege A, et al. Subclinical hepatic encephalopathy: The diagnostic values of evoked potentials. J Hepatol 1995;22:101-10.
12. Yang SS, Wu CH, Chiang TR, et al. Somatosensory evoked potentials in subclinical portosystemic encephalopathy: A comparison with psychometric tests. Hepatology 1998;27:357-61.
13. Quero JC, Hartmann IJC, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996;24:556-60.
14. Spahr L, Butterworth RF, Fontaine S, et al. Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996;24:1116-20.
15. 1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993;43:65-9.
16. Kulisevsky J, Pujol J, Balanzó J, et al. Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: Clinical correlations. Hepatology 1992;16:1382-8.
17. Butterworth RF, Spahr L, Fontaine S, et al. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metabolic Brain Dis 1995;10:259-67.
18. Pomier-Layrargues G, Spahr L, Butterworth RF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 1995;345:735 (letter).
19. Krieger D, Krieger S, Jansen O, et al. Manganese and chronic encephalopathy. Lancet 1995;346:270-4.
20. Huang CC, Chu NS, Lu CS, et al. Chronic manganese intoxication. Arch Neurol 1989;46:1104-6.
21. Mirowitz SA, Westrich TJ. Basal ganglia signal intensity alterations: Reversal after discontinuation of parenteral manganese administration. Radiology 1992;185:535-6.
22. Devenyi AG, Barron TF, Mamourian AC. Dystonia, hyperintense basal ganglia and whole blood manganese levels in Alagille's syndrome. Gastroenterology 1994;106:1068-71.
23. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-6.
24. Conn HO. Trail Making and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Dig Dis 1977;22:541-50.
25. Lezak MD. A compendium of tests and assessment techniques. In: Lezak MD, ed. Neuropsychological assessment. New York: Oxford University Press, 1983.
26. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
27. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc 1992;40:922-35.
28. Hely MA, Chey T, Wilson A, et al. Reliability of the Columbia scale for assessing signs of Parkinson's disease. Mov Disorders 1993;8:466-72.
29. Spahr L, Vingerhoets F, Lazeyras F, et al. Magnetic resonance imaging and proton spectroscopic alterations correlate with Parkinsonian signs in patients with cirrhosis. Gastroenterology 2000;119:774-81.
30. Groeneweg M, Moerland W, Quero JC, et al. Screening of subclinical encephalopathy. J Hepatol 2000;32:748-53.
31. Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-73.
32. Amodio P, Marchetti P, Del Piccolo F, et al. Visual attention in cirrhotic patients: A study on covert visual attention orienting. Hepatology 1998;27:1517-23.
33. Krieger S, Jaub M, Jansen O, et al. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996;111:147-55.
34. Kono I, Ueda Y, Nakajima K. Subcortical impairment in subclinical hepatic encephalopathy. J Neurol Sci 1994;126:162-7.
35. Dubois B, Pilon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
36. Levin B, Llabre M, Weiner W. Visuospatial impairment in Parkinson's disease. Neurology 1991;41:365-9.
37. Levin B, Llabre M, Weiner W. Cognitive impairments associated with early Parkinson's disease. Neurology 1989;39:557-61.
38. Bermejo F, Enguita MA, Del Ser T. Depresión y demencia en la enfermedad de Parkinson. Med Clin (Barc) 1986;87:90-5.
39. Brown P, Marsden CD. What do the basal ganglia do? Lancet 1998;351:1801-4.
40. Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999;117:640-4.
41. Pomier Layrargues G, Rose C, Spahr L, et al. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis 1998;13:311-7.
42. Montes S, Alcaraz-Zubeldia M, Muriel P, et al. Striatal manganese induces changes in dopamine metabolism in the cirrhotic rat. Brain Res 2001;891:123-9.
43. Hazell AS, Norenberg MD. Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res 1997;22:1443-7.
44. 3H-PK 11195. Neurosci Lett 1999;271:5-8.
45. Hazell AS. Norenberg MD. Ammonia and manganese increase arginine uptake in cultured astrocytes. Neurochem Res 1998;23:869-73.